THOUSAND OAKS, Calif., July 9 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) announced today that its Board of Directors has appointed Rebecca M. Henderson, Ph.D., to the Company's Board. Dr. Henderson, 48, has recently joined the faculty at the
Dr. Henderson has also been a research associate at the National Bureau of Economic Research since 1995. She also sits on the editorial boards of Management Science, Research Policy and Organization Science.
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks Mary Klem, 805-447-6979 (media) Arvind Sood, 805-447-1060 (investors)
Copyright©2009 PR Newswire.
All rights reserved